Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: Results from the ATHENA study

Europace

Volumn 13, Issue 8, 2011, Pages 1118-1126

  Torp Pedersen, Christian ^a   Crijns, Harry J G M ^b   Gaudin, Christophe ^c   Page, Richard L ^d   Connolly, Stuart J ^e   Hohnloser, Stefan H ^f  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f GOETHE UNIVERSITY   (Germany)

Author keywords

Anti arrhythmic drug; Atrial fibrillation; Dronedarone; Hospitalization

Indexed keywords

DRONEDARONE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR INFECTION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART SIZE; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HOSPITALIZATION; HUMAN; HYPERTENSION; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; STABLE ANGINA PECTORIS; SYNCOPE; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

EID: 80051724296     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur102     Document Type: Article

References (23)

1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004;110:1042-46. (Pubitemid 39319000)
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25. (Pubitemid 44420743)
3. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;86: 516-21. (Pubitemid 32999861)
4. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
5. Steger C, Pratter A, Martinek-Bregel M, Avanzini M, Valentin A, Slany J et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: Data from the Austrian Stroke registry. Eur Heart J 2004;25:1734-40. (Pubitemid 39286639)
6. WattigneyWA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: Implications for primary prevention. Circulation 2003;108:711-16. (Pubitemid 36999256)
7. Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. Eur Heart J 2001;22:693-701. (Pubitemid 32622430)
8. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Seward JB et al. Changing trends of hospital utilization in patients after their first episode of atrial fibrillation. Am J Cardiol 2008;102:568-72.
9. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666-72. (Pubitemid 40417013)
10. Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: Report from the Stockholm Cohort Study of Atrial Fibrillation. Europace 2011; advance access publication 6 April 2011, doi: 10.1093/Europace/eur100.
11. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
12. Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C. Rationale and design of ATHENA: A Placebo-controlled, Double-blind, Parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/ atrial flutter. J Cardiovasc Electrophysiol 2008;19:69-73.
13. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;10:1360-420.
14. Wyse DG, Slee A, Epstein AE, Gersh BJ, Rocco T Jr, Vidaillet H et al. AFFIRM Investigators. Alternative endpoints for mortality in studies of patients with atrial fibrillation: The AFFIRM study experience. Heart Rhythm 2004;1:531-7. (Pubitemid 39462710)
15. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77. (Pubitemid 351860859)
16. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 2001;104:292-6. (Pubitemid 32666950)
17. Manning A, Thisse V, Hodeige D, Richard J, Heyndrickx JP, Chatelain P. SR 33589, a new amiodarone-like antiarrhythmic agent: Electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol 1995;25:252-61.
18. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-16.
19. Gö gelein H, Ruetten H. Effect of dronedarone, a new multichannel blocking agent, on sodium and HCN4 channels in vitro. Clin Res Cardiol 2009;98(Suppl 2):P329.
20. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010;376:875-85.
21. Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL et al. ATHENA Investigators. Analysis of stroke in ATHENA: A Placebo-controlled, Double-blind, Parallel Arm Trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009;120: 1174-80.
22. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: A systematic review of randomized controlled trials. Arch Intern Med 2006; 166:719-28.
23. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A Short-term, Randomized, Double-blind, Parallel-group Study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study. J Cardiovasc Electrophysiol 2010;21:597-605.